

Gene-environment interactions in addictive disorders: epidemiological and methodological aspects.

Philip Gorwood, Mathias Wohl, Yann Lestrat, Frédéric Rouillon

► **To cite this version:**

Philip Gorwood, Mathias Wohl, Yann Lestrat, Frédéric Rouillon. Gene-environment interactions in addictive disorders: epidemiological and methodological aspects.. Comptes Rendus Biologies, Elsevier Masson, 2007, 330 (4), pp.329-338. 10.1016/j.crv.2007.02.017 . inserm-00150412

HAL Id: inserm-00150412

<https://www.hal.inserm.fr/inserm-00150412>

Submitted on 31 May 2007

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Gene-Environment interactions in addictive disorders: epidemiological and methodological aspects.

Interactions gène - environnement dans les pathologies addictives: aspects méthodologiques et épidémiologiques.

Philip Gorwood^{1,2}, Mathias Wohl^{1,2}, Yann Le Strat^{1,2}, Frédéric Rouillon³

Keywords: dependence, vulnerability, alcohol, drug, interaction, genetic, environment

Mots-clé: dépendance, vulnérabilité, alcool, drogue, génétique, facteurs environnementaux.

1. INSERM U675, Institut Fédératif de Recherche (IFR 02), Faculty of Xavier Bichat
16 rue Henri Huchard, 75018 Paris, France.
2. AP-HP. Service de Psychiatrie Adulte, Faculty of Bichat-Claude Bernard, Louis
Mourier Hospital (AP-HP, Paris VII), 178 rue des Renouillers, 92701 Colombes
Cedex, France.
3. CMME-Sainte Anne (Paris V). France

Correspondence:

Philip Gorwood, MD, PhD

INSERM U675, Faculty of Medicine Bichat (IFR02). 16 rue Henri Huchard, 75018 Paris, France.

Tel : (33) 1 47 60 64 15 Fax : (33) 1 47 60 67 40

e-mail : philip.gorwood@lmr.aphp.fr

Abstract:

Gene-Environment interactions approach could explain some epidemiological and clinical factors associated to addictive behaviors. Twin studies first help to disentangle the respective role of environment and genetic effects, finding convincing evidence for common genetic vulnerability in several addictive behaviors, and helping to delimit what syndrome could belong to the addictive disorder spectrum. Assessing gene x environment interaction (GxE), need specifically designed studies, using multiplicative or additive approaches. Focusing on this GxE interaction already showed its relevancy in many recent studies, using both epidemiological and molecular approaches. For example, in a non-human primate model of alcohol dependence assessing the respective role of genetic vulnerability (having the short allele located in the promoter region of the gene coding for the serotonin transporter) and severe fostering conditions (as locked up in a cage with other inmates for the first 6 months of life), the only group that has a significant risk of using spontaneously alcohol is the group of monkeys that have both risk factors, i.e. being peer-raised and having the short allele. Such approach could help to more accurately select specific candidate genes, to identify more homogenous subgroups of patients (as sharing the same genetic vulnerability), to understand how genetic factors mediate the risk for associated psychiatric disorders, and ultimately, may lead to more focused, i.e. more efficient, prevention strategies.

Résumé

Les études épidémiologiques sont informatives et concordantes quant aux facteurs faisant varier en fréquence les conduites addictives (sexe, âge, statut marital, trouble psychiatrique et surtout dépendance à une autre substance). Or, le rôle de ces facteurs dont certains relèvent de l'environnement est à confronter à l'importance d'une vulnérabilité génétique aux addictions. Les études de jumeaux aident à quantifier le poids respectif de l'environnement et de l'hérédité. Elles retrouvent de manière homogène un poids significatif des gènes dans la vulnérabilité aux dépendances quelque soit la substance voir l'objet de cette dépendance (substances ou comportement). Plus encore, ces études montrent qu'au sein de l'hérédité des addictions, une vulnérabilité génétique commune compte plus que la part spécifique de gène à chaque dépendance. Elles aident ainsi à préciser le phénotype héritable comme relevant de conduites addictives associées entre elles et à d'autres troubles comportementaux comme les conduites agressives précoces et l'hyperactivité.

Pour autant, malgré les arguments en faveur de l'intervention de gènes majeurs dans cette vulnérabilité, aucun allèle n'a pu être clairement impliqué. L'hétérogénéité du phénotype, les phénomènes de phénocopies et de pénétrance incomplète, comme les interactions épistatiques pourraient expliquer ces difficultés. La prise en compte conjuguée des facteurs génétiques et environnementaux doit permettre de mieux déterminer les facteurs de vulnérabilité impliqués ainsi que la manière dont ils s'associent.

L'étude de l'interaction gène-environnement (GxE) apporte certains éléments de réponse. Plusieurs méthodes permettent d'estimer cette interaction. La première dite « multiplicative » mesure si l'exposition aux deux facteurs ($RR(GxE)$) présente un risque relatif au dessus ou en dessous de celui attendu en multipliant le risque relatif du facteur environnemental ou génétique isolément. La deuxième méthode est dite « additive ». Elle compare simplement la différence entre le risque lié à la présence des deux facteurs à l'addition des risques de chacun

d'entre eux. Ces différentes méthodes permettent de différencier la corrélation gène-environnement (rGE) de l'interaction GxE proprement dite. Cette approche peut ainsi permettre d'identifier les groupes les plus génétiquement vulnérables à l'environnement. Elle a ainsi son importance dans les stratégies de prévention.

Certaines études récentes ont prouvés ce type d'interaction. Par exemple, une étude d'adoption montre que les conduites agressives de l'enfant adopté étaient associées en fréquence à une alcoolodépendance chez les parents biologiques uniquement en cas d'environnement familial perturbé dans la famille adoptive. Ce type d'interaction est également montré au niveau moléculaire. Dans une étude portant sur les singes rhésus, la séparation précoce du nouveau né entraîne un risque de consommation d'alcool uniquement en présence de l'allèle court d'un polymorphisme du promoteur de la sérotonine. Chez l'homme, ce type d'interaction est montré par des protocoles de pharmacogénétique (variation de l'efficacité de la Naltrexone dans la dépendance à l'alcool en fonction d'un polymorphisme d'un récepteur opioïde); ou dans la sévérité des symptômes de sevrage à l'alcool, voire des complications de sevrage en fonction du génotype du transporteur de la dopamine. Ces résultats chez l'homme sont d'autant plus pertinents qu'ils concernent tous deux des molécules centrales du système de récompense, voie biologique candidate principale dans la vulnérabilité aux dépendances en général.

La mesure précise de ce type d'interaction GxE s'est donc déjà montrée pertinente. Elle devrait se poursuivre sur des échantillons conséquents, permettant de définir d'une part les environnements précisément « à risque », d'autre part, les gènes de vulnérabilité, et enfin, la manière dont ils s'associent dans les troubles psychiatriques, pathologies éminemment multifactorielles.

1. Epidemiology of addictive disorders

Alcohol and illicit drug abuse are among the top 10 major risk factors in global burden of mortality and morbidity according to the assessments based on the DALY (Disability adjusted life years) [1]. Epidemiology of addictive disorders need to analyse both clinical and general population samples to understand the complex relationships between drinking/ drug use, drinking problems/drug related problems, alcohol/drug abuse or dependence and to measure consequences (mortality, somatic and psychiatric co-morbidity, social difficulties, antisocial and criminal behaviours,...) of these addictions.

The estimations of abuse and dependence prevalences for any type of addictive substance are based on a limited number of studies. Five large epidemiologic researches based on the general population have examined the co-morbidity of alcohol and drug use disorders worldwide. The Epidemiologic Catchment Area (ECA) in the 1980s [2], the National Comorbidity Survey (NCS) [3], the National Longitudinal Alcohol Epidemiologic Survey (NLAES) [4] were all made in the United States of America. The 1990 Mental Health Supplement of the Ontario Canada Health Survey (MHS-OHS: [5]) and the 1997 Australian National Survey of Mental Health and Well Being (NSMHWB: [6]) were also derived from a large sample of the general population. Unfortunately, such a study was not performed in France, although the latter has one of the most important consumption of alcohol in the world. Indeed, according to one study focusing on consumption, the French general population (between 18 and 75 years old) had a high prevalence rates of alcohol regular use (31%), tobacco (29%), cannabis (1,4%) and cocaine or heroin (0.4%) in 2002 [7]. The only information we have is derived from the ESCAPAD study, a one month prevalence of drug use among young people, between 17 and 18 years old. The estimated prevalence was 1% for

poppers, 0.7 % for solvents, 0.9% for cocaine, 0.9% for amphetamines, 0.5% for LSD, 1.6% for Ecstasy, 0.4% for Heroin and 0.3% for crack [8].

The most interesting study on this topic is the NESARC [9], which recently analysed a large (more than 43,000 subjects) representative sample of the U.S. population, examining current prevalences and associations between alcohol and specific drug use disorders.

The one-year prevalence rates of abuse or dependence are ranging from 0.02% (cocaine dependence) to 1.13% for cannabis abuse (Table I). These frequencies are limited to syndromic addictions that were observed during the current year.

More interestingly, a large number of parameters were analysed in the groups of patients with, or without, any addictive disorder (Table II). It can be observed that not only males are more exposed to any addictive disorders, but they are also more exposed to co-morbid addictive disorders (alcohol and drug abuse or dependence). One of the interesting ideas of the NESARC study was to enrich subgroup of subjects from ethnic minorities. With this approach, they showed that African persons are more exposed to any drug abuse or dependence, Asians are less exposed to alcohol abuse or dependence, and subjects with Hispanic origins are more frequently observed in the group of co-morbid addictive disorders. The NESARC study also confirmed that young subjects (18-29) are more at risk, as subjects who were never married. Personality disorder and past year anxiety or mood disorders were associated with a dramatic increase of any abuse or dependence diagnosis, an important result regarding the effort which was made in the NESARC study to correctly assess such co-morbidity, usually very difficult to disentangle. Another major replication of the NESARC investigation is the very high co-morbidity of addictive dependencies, presence of one dependence dramatically increasing the risk of dependence for another substance (table III), up to 43 times increased risk (OR=43) of alcohol dependence in patients with cocaine dependence.

The role of environmental risk factors is not in contradiction with a genetic approach of addictive disorders, as vulnerability genes might lead to the disorder through these factors. For example if genes coding for male hormones are involved in opiate dependence, gender is a risk factor through genetics. An alternative explanation is that environmental factors might decrease the threshold, allowing the genetic vulnerability to be expressed. For example, if stressful life events are associated with an increased risk of relapse in alcohol dependence, the role of the gene coding for the serotonin transporter (the target of antidepressive drug) might be involved, and only observable in patients exposed to such revealing conditions.

2. Genetics of addictive disorders

The heritability concept relates to the percentage of the total variance of a disorder that is explained by genes. It is usually computed on the basis of twin studies that help to disentangle the respective role of the specific environment (the part of the environment that is not shared by the two twins in the same family, whether they are monozygotic or dizygotic), the shared or family environment (by definition comparable between two twins raised in the same families, at the same period of time... roughly comparable for monozygotic and dizygotic twins) and addictive genetic effects (i.e., heritability, which is nearly the only source of difference between the two types of twins). Indeed, monozygotic twins share 100% of their genes (as it is the same oocyte, fertilized by the same spermatoid, that led to only one embryo which is accidentally divided in two after fertilization) and dizygotic twins share only 50% of their genes (as they come from two different oocytes, fertilized by two different spermatoids, as all sibs).

Many twin studies were performed on addictive disorders. In alcohol consumption, the heritability is relatively high ($h^2=43\%$) [10], as it is for tobacco use, especially for those that

consume a large amount of cigarettes per day (h^2 up to 70%) [11]. Usage of hallucinogens, opiates and sedatives are also associated with a relatively high heritability [12].

Interestingly, the role of shared (familial) environment is usually not significantly different from 0, at least for hallucinogens, opiates and sedative [12], the involved risk factors could therefore mainly concern genes and specific environment. The heritability of addictive disorders is largely variable from one study to another, which is not surprising as patients are collected in very different ways, using different instruments and collected from different settings. The Virginie cohort from Kendler and some of the Australian studies relate to the general population, and a large part of other studies are based on treated population. Roughly, the heritability of addictive disorders is higher for abuse than for usage, and for dependence than for abuse, ranging between 21% and 72%. The heritability scores of substance abuse or dependence have surprisingly a low level of covariance with the heritability score observed in substance consumption., i.e., the genes involved in consumption are not systematically involved in abuse or dependence, and vice-versa.

Some twin studies focused on this problem, assessing the cross-twin cross-trait heritability to pinpoint the shared heritability between two different addictive disorders. Tsuang et al. [13], for example, showed that a large majority of the genes involved are common to the different disorders, with the role of genes for one specific disorder being 0% for LSD, 15% for sedatives, 25% for stimulants and 33% for cannabis [13]. In another study, the co-morbidity between pathological gambling and alcohol dependence is mainly depending on the same genes, the heritability ranging between 12% and 75% [14-15]. All studies are not that clear for the existence of a common genetic basis in the different addictive disorders [16].

Nevertheless, when researches are focusing not only to initiation, maintenance or level of consumption, but rather on dependence symptoms, then the involved genes might be much

more frequently common than different, explaining in part, for example, the high comorbidity between cigarette and alcohol dependence [17].

Few studies have been performed on behavioural addictive disorders, such as pathological gambling. In the same line with what is observed for chemical addictions, the more frequent an addictive behaviour is performed with deleterious consequences, the higher is the heritability ($h^2=35\%$ when the gambling was made at least 25 times a year, and 54% when two symptoms of pathological gambling are detected).

It is not easy to delimit what syndrome belongs to the addictive disorder spectrum. Indeed, Cloninger [18] showed that alcohol dependence is not really inherited, but rather that a subgroup of patients is especially concerned by genetic vulnerability, with young age at onset, severe dependence, male gender, and antisocial behaviour, this group of patients explaining a large proportion of the alcohol dependence heritability. Such type II male limited alcoholism has in fact a 88% heritability, while type I alcoholism only has a heritability of 21% .

3. The definition of GxE interaction

The fact that so important evidence favours the hypothesis of a major role of genes in the development of any abuse or dependence is counterbalanced by the absence of vulnerability genes that has yet been definitely involved. Indeed, the only genes that have a clear-cut role in alcohol or tobacco dependence are more devoted to protection than to vulnerability [19], and are related to the metabolism of the drug rather than to temperament, psychiatric vulnerability, or social behaviour. Many reasons could be raised to explain such discrepancy.

- The absence of valid criteria for the concepts of abuse or dependence is an important limitation, as the criteria used for the diagnosis are chosen for their clinical relevance, not according to genetic studies.

- Presence of phenotypical heterogeneity is also a source of problem, as not all cases of addictive disorder for different types of drug or behavior share the same mechanisms. Accordingly, analysing samples of patients with different type of dependence, based on different risk factors (see table II) may add confusion rather than increase the power of the statistical analyses.

- The “phenocopy” and “incomplete penetrance” phenomenon could act as a break upon the discovery of vulnerability genes too. Some patients may indeed have a dependence for reasons that are independent of genetic vulnerability, (i.e., phenocopy) and not all cases of genetically vulnerable patients will have the disorder at least once in their life (i.e., incomplete penetrance)

- Epistatic interaction (i.e., different combination of genes might explain the disorder rather than isolated gene) is also rarely taken into account in genetic analyses of addictive disorders.

A highlighting way of facing these problems is mixing the approaches devoted to environmental factors with those devoted to genetic analyses. Such gene x environment interaction (usually untitled “GxE interaction”), is a domain of research that only recently led to specifically designed studies, and which may constitute an interesting way of dealing with phenotypical heterogeneity. Looking at the role of a gene in a group of patient sharing the same environmental risk factor does clearly reduce the heterogeneity of the phenotype. The limitations of phenocopy and incomplete penetrance are also largely reduced this way, for the

same reasons. Furthermore, the reliability of the studied concepts could be considered as enhanced when both environmental and genetic aspects are considered.

For example, being male, Caucasian, between 18 and 29 years old, never married, with a low level of education, with a personality disorder and with lifetime mood and/or anxiety disorder is associated with a dramatically increased risk of any addictive disorder. Such group of patients has more chance to share common vulnerability genes, as they represent a more homogenous sample. Specific risk factors may also help to pinpoint some candidate genes.

For example, as mood disorder is associated with an increased risk of alcohol or drug abuse/dependence, patients with both alcohol dependence and independent major depressive disorder could have more chance to have vulnerability genes involved in these two disorders, such as those related to serotonin receptors, transports and metabolism.

The way to assess GxE interaction can be written in a table (table IV) or presented in a figure (figure 1). There are several methods to assess the statistical significance of interactions [20].

The first one is multiplicative, and measure if those exposed to both risk factors ($RR[GxE]$) have a relative risk which is above (supermultiplicative) or below (submultiplicative) the one expected by multiplying the relative risk for environmental exposure ($RR[E]$) or genetic predisposition alone ($RR[G]$). This leads to assess if $RR[GxE]$ is greater than the multiplication of $RR[G]$ and $RR[E]$. The second method is an additive approach, and focuses on differences between the risk observed in $RR[GxE]$ (exposed to both risk factors) and $RR[E] + RR[G]$ (adding the two individual risks).

Other types of advantages can be raised for the GxE interaction approach. For example, the statistical power of the analyses might be particularly crucial in complex disorders and neuroscience research. If a gene has a moderate global role but a strong effect in a subsample (that share common vulnerability factors), limiting the analyses to this group of patients may help to discover genes that would never have been found in the general population.

Furthermore, the path between presence of vulnerability factors to the onset of an addictive disorder should be easier to understand, as genetic are always the first risk factors in the causal chain. When analysing the performance of prevention strategies, such approach could lead to focus on more vulnerable group(s) (i.e. those with vulnerability genes) in order to avoid (if possible) the environmental vulnerability factors, or alternatively to reinforce their coping strategies in order to reduce the deleterious effect of such environmental factor.

4. Evidence for and examples of GxE interactions in addictive disorders

Before the first molecular genetic analyses have been performed in different addictive disorders, evidence was raised in favour of a GxE interaction in the 80's. In an adoption study, Cadoret et al. [21] showed, for example, that both presence of alcohol dependence in the educative parents and presence of alcohol dependence in biological parents (who did not raise their children) are risk factors for alcohol dependence in adoptive children, showing that genetic and familial environmental factors are both involved. Interestingly, he found that alcohol dependence in the biological parents increased the risk of aggressivity of the adoptive child, and that this aggressivity leads to antisocial disorder (OR=8.9) only when the children are raised in a disturbed adoptive family (OR=3.2). Antisocial personality disorder being the most important risk factor for any alcohol or drug abuse or dependence, a GxE interaction was therefore shown.

One particularity of GxE analysis (genetically influenced sensitivity to the environment) relates to rG.E correlation (association between genetic and environmental risks), when the genetic factors are not associated with a more deleterious effect of an environmental stress, but rather increases the risk to be exposed to such negative elements.

Such bias may lead to erroneous conclusions as it is not a real interaction, but rather a correlation of these two risk factors. A heuristic example of such rG.E correlation was detected when assessing the heritability of cigarette smoking in different cohorts according to age. Kendler showed [22] that the heritability of cigarette smoking is around 60% for young cohorts of male and female subjects. But for female patients around 60 years old the heritability drop to 20%, and is not any more significantly different from 0 for even older cohorts (born between 1910 and 1924). Interestingly, the heritability of tobacco smoking is not variable in male cohorts according to age. This study shows that when access to an addictive substance is decreasing (for life habits, social image or other reasons), the chance to prove a role of genetic factors is also decreasing. Indeed, with very few tobacco dependence in old female cohorts (probably because in the past cigarette smoking was considered as a male behaviour) it was not possible to analyse any risk factor, as social gaiting was censoring all other factors.

A more direct assessment of GxE interaction was tested in a non-human primate model of alcohol dependence [23]. In this protocol, young rhesus monkeys were split in two groups according to a genetic polymorphism of the promoter region of the serotonin transporter (5-HTT), those having, or not, the short variant of the 5-HTTLPR polymorphism. This allele was previously associated to alcohol dependence [24,25] and has the particularity to be perfectly common in human and non-human primates. As this gene was also associated with mood and anxiety disorder, the authors made the hypothesis that very stressful upbringing conditions would enhance their risk to maintain initially induced alcohol consumption (environmental effect), especially in vulnerable monkeys (genetic effect). In accordance with their hypothesis, the monkeys that were separated from their mothers at birth and locked up in a cage with other inmates (i.e. peer-raised) for the first 6 months of life had a

HAL author manuscript inserm-00150412, version 1

higher alcohol consumption, whereas monkeys with the short allele also had an increased spontaneous alcohol consumption. The striking finding is in fact that none of these two factors should have been considered alone, as being peer-raised is not associated with an increase of alcohol consumption when the rhesus monkeys do not have the short allele, and as having the short allele is not associated with an increased alcohol consumption in the group of monkeys that were raised by their mother. Indeed, the only group that has a significant risk of using spontaneously alcohol is the group of monkeys that have both risk factors, i.e. being peer-raised and having the short allele.

Another aspect of GxE interaction in addictive disorders relates to psychopharmacogenetics. The treatment can be considered as an environmental effect on a subject, which might be variable according to different genetic polymorphisms. For example, naltrexone has shown a good efficacy in alcohol dependence [26]. The role of naltrexone is to reduce, after withdrawal, the risk of relapse, the intensity of alcohol craving and days in which alcohol is consumed. However, positive response to naltrexone is variable [27]. The endogenous opioid system was therefore assessed as a potential predictor of treatment response, as naltrexone exerts its action as a mu receptor antagonist. One such psychopharmacogenetic study analysed the impact of a μ -opioid receptor *OPRM1* gene polymorphism on naltrexone efficacy in 82 alcohol-dependent patients compared to 59 controls, namely alcohol-dependent patients who were randomized to placebo [28]. Subjects with one or two copies of the 118G allele have shown a significantly lower rate of relapse and a longer time to return to heavy drinking than patients homozygous for the 118A allele.

As the mesolimbic dopaminergic system plays a key role in reward pathway, the genes involved in central dopamine functions are frequently studied in alcohol dependence. The

gene encoding the dopamine transporter (DAT) could be a good candidate gene because this membrane-bound protein is essential for the homeostatic regulation of dopaminergic neurotransmission [29]. Given the heterogeneous results of the case-control association studies, particularly those on alcohol-dependent patients, it may be interesting to restrict this kind of study to more homogeneous subgroups of patients, taken into account the environmental effects. A key period to assess dependence is the withdrawal period, as acutely stopping alcohol consumption is an environmental factor that may highlight genetic vulnerability to severe dependence. A significant association between the 9-copy repeat allele (A9 allele) of a variable-number tandem repeat in the 3' untranslated region of the DAT gene and two withdrawal complications, namely delirium tremens and alcohol withdrawal seizure were reported [30-31]. In addition, Schmidt *et al.* [32] found that withdrawal symptoms were more severe in alcohol-dependent patients carrying the A9 allele than among patients without this variant. Wernicke *et al.* also [33] tested two other polymorphisms in the 3'UTR of the DAT gene, and found a higher prevalence of A/A homozygosity in patients with a history of severe complications. Lastly, the only sample that analyzed female alcohol dependent patients showed also that the A9 allele could constitute a risk factor for severe withdrawal complications, in this sample, patients with the A9 allele have more hallucinations than those without the vulnerability allele [34]. Therefore, the role of the DAT gene is not increasing the risk of alcohol dependence per se, but rather, when patients are exposed to an acute withdrawal of their consumption, is associated with an increased risk of life-threatening complications, at least for five different studies. Putting to the fore this vulnerability gene in alcohol dependence thus required to determine (for hospitalized patients in order to get abstinence), control (when treating alcohol dependent outpatients, a strict medical supervision is required) or at least assess (as accidental withdrawal periods exist, it is important to measure the suddenness and length of such phases) withdrawal conditions, this specific

situation constituting an environmental trigger that allowed to show the role of a vulnerability gene.

5. Conclusions

Assessing the role of the environment factors that are involved in addictive disorders while taking into account the existence of a genetic vulnerability is logical, this being true the other way round. On the other hand, adding another factor, and taking into account the interaction between different these two factors, also have some limitations. Assessing GxE interactions is more difficult as requiring specially designed studies [20], as they are more informative in large cohort of different subgroups initially selected on the basis of presence versus absence of each risk factor and followed-up for long period of times. Hence, this type of protocol is particularly difficult to perform in such populations with large drop out rates, and such disorder that has so many environmental risk factors (each with a moderate to low impact) and with no gene already considered as obviously involved. Moreover, environmental risk factors are different from early embryonic development through gestation and birth and onward toward children and later stages of development [35].

Nevertheless, focusing on this GxE interaction already showed its relevancy. Facing the environmental factors involved to the genetic vulnerability helps to select specific candidate genes. Delimiting definite sets of environmental risk factors also favour the selection of more homogenous subgroups of patients that have higher chance to share the same vulnerability genes. Moreover, psycho-experimental protocols can also be proposed, as some of the environmental factors are controllable. Assessing the initial tolerance to the cognitive and motor effect of moderate amount of alcohol injection in sons of alcohol dependent fathers [36] was already analyzed, for example, with interesting genetic results. In

addition, prevention strategies would gain in efficacy when focusing on vulnerable groups (as having the vulnerability allele) and specific sets of environmental factors (trying to reduce its deleterious impact).

The shift from purely environmental studies to genetic research in addictive disorder is still recent, with promising but up to now disappointing results. Such cleavage probably has an internal coherence (not using the same tools) but probably has to be overtaken to get closer to what is happening in real life, i.e. the way we cope with addictive substances is a mix up of many environmental effects, the genes that we are made of, and a large interaction between these two phenomenon.

6. References

- [1] Murray and Lopez, *The Global Burden of Disease*, in: C. Murray and A. Lopez (Eds), Harvard Press. Cambridge, MA, 1996.
- [2] D.A. Regier, M.E. Farmer, D.S. Rae, B.Z. Locke, S.J. Keith, L.L. Judd, F.K. Goodwin, Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study, *JAMA* 264 (1990) 2511–2518.
- [3] R.C. Kessler, R.M. Crum, L.A. Warner, C.B. Nelson, J. Schulenberg, J.C. Anthony, Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey, *Arch. Gen. Psychiat.* 54(1997) 313–321.
- [4] B.F. Grant, DSM-III-R and proposed DSM-IV alcohol abuse and dependence United States 1988: a nosological comparison, *Alcohol Clin. Exp. Res.* 16 (1992) 1068–1075.
- [5] H.E. Ross, DSM-III-R alcohol abuse and dependence and psychiatric comorbidity in Ontario: results from the Mental Health Supplement to the Ontario Health Survey, *Drug Alcohol Depend.* 39 (1995)111–128.
- [6] W. Hall, M. Teeson, M. Lynskey, L. Degenhardt, The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey on Mental Health and Well-Being, *Addiction* 94 (1994)1541–1550.
- [7] O.F.D.T. (Observatoire Français des Drogues et des toxicomanies). *Drogues et dépendances, données essentielles- Guides Ed. La Découverte ; Paris ; 202p. ; 2005.*
- [8] F. Beck, S. Legleye, *Drogues et adolescence: usages de drogues et contextes d’usage entre 17 et 19 ans, évolution récentes . ESCAPAD 2002. OFDT, Paris (2003) 164p.*
- [9] F.S. Stinson, B.F. Grant, D.A. Dawson, W.J. Ruan, B. Huang, T. Saha, Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions, *Drug Alcohol Depend.* Oct 1;80(1) (2005)105-16.
- [10] P. Gorwood, Facteurs génétiques de l’alcoolisme. In : Masson (Eds), J Adès, M. Lejoyeux. *Alcoolisme et Psychiatrie. Collection Médecine et Psychothérapie, 1997, 25-40.*
- [11] N. Hiroi, S. Agatsuma, Genetic susceptibility to substance dependence, *Mol Psychiatry*, 10(4) (2005) 336-44.
- [12] K.S. Kendler, L. Karkowski, C.A. Prescott, Hallucinogen, opiate, sedative and stimulant use and abuse in a population-based sample of female twins, *Acta Psychiatr Scand.*, 99(5) (1999) 368-76.
- [13] M.T. Tsuang, M.J. Lyons, J.M. Meyer, T. Doyle, S.A. Eisen, J. Goldberg, W. True, N. Lin, R. Toomey, L. Eaves, Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities, *Arch Gen Psychiatry*, 55(11) (1998) 967-72.

- [14] S.A. Eisen, W.S. Slutske, M.J. Lyons, J. Lassman, H. Xian, R. Toomey, S. Chantarujikapong, M.T. Tsuang, The genetics of pathological gambling, *Semin Clin Neuropsychiatry*, 6(3) (2001) 195-204.
- [15] W.S. Slutske, S. Eisen, W.R. True, M.J. Lyons, J. Goldberg, M. Tsuang, Common genetic vulnerability for pathological gambling and alcohol dependence in men, *Arch Gen Psychiatry*, 57(7) (2000) 666-73.
- [16] J.M. Hettema, L.A. Corey, K.S. Kendler, A multivariate genetic analysis of the use of tobacco, alcohol, and caffeine in a population based sample of male and female twins, *Drug and Alcohol Dependence*, 57 (1999) 69-78.
- [17] W.R. True, H. Xian, J.F. Scherrer, P.A. Madden, K.K. Bucholz, A.C. Heath, S.A. Eisen, M.J. Lyons, J. Goldberg, M. Tsuang, Common genetic vulnerability for nicotine and alcohol dependence in men. *Arch Gen Psychiatry*, 56(7) (1999) 655-61.
- [18] C.R. Cloninger, S. Sigvardsson, S.B. Giligan et al, Genetic heterogeneity and the classification of alcoholism, *Adv Alcohol Subst Abuse*, 7(3-4) (1988) 3-16.
- [19] P. Gorwood, G. Schumann, J. Treutlein, J. Adès, Pharmacogenetics of alcohol dependence, In: *Psychopharmacogenetics*. Edited by Philip Gorwood & Michel Hamon. Springer Inc., 2006, pp177-202.
- [20] D. Hunter, Gene-environment interactions in human diseases, *Nature Reviews, Genetics*. April 6 (2005)287-298.
- [21] R.J. Cadoret, E. Troughton, T.W. O'Gorman, E. Heywood, An adoption study of genetic and environmental factors in drug abuse, *Arch Gen Psychiatry*, Dec;43(12) (1986)1131-6.
- [22] K.S. Kendler, L.M. Thornton, N.L. Pedersen, Tobacco consumption in Swedish twins reared apart and reared together, *Arch Gen Psychiatry*, Sep;57(9) (2000) 886-92.
- [23] C.S. Barr, T.K. Newman, S. Lindell, C. Shannon, M. Champoux, K.P. Lesch, S.J. Suomi, D. Goldman, J.D. Higley, Interaction between serotonin transporter gene variation and rearing condition in alcohol preference and consumption in female primates, *Arch Gen Psychiatry*. Nov;61(11) (2004)1146-52.
- [24] P. Gorwood, P. Batel, J. Adès, M. Hamon, C. Boni, Serotonin transporter gene polymorphisms, alcoholism and suicidal behaviour, *Biological Psychiatry*, 48(4) (2000) 259-264.
- [25] P. Gorwood, L. Lanfumey & M. Hamon, Polymorphismes géniques de marqueurs sérotoninergiques et alcool-dépendance, *Medecine/Sciences*, 20(12) (2004) 1132-1138.
- [26] J.C. Garbutt, H.R. Kranzler, S.S. O'Malley, D.R. Gastfriend, H.M. Pettinati, B.L. Silverman, J.W. Loewy and E.W. Ehrich Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial, *JAMA*. 293 ,(2005) 1617-1625.

- [27] K. Mann, Pharmacotherapy of alcohol dependence: a review of the clinical data, *CNS Drugs* 18 (2004) 485-504.
- [28] D.W. Oslin, W. Berrettini, H.R. Kranzler, H. Pettinati, J. Gelernter, J.R. Volpicelli and C.P. O'Brien, A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients, *Neuropsychopharmacology* 28 (2003) 1546-1552.
- [29] B. Giros, M. Jaber, S. Jones, R. Wightman, M. Caron, Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter, *Nature*, 379 (1996) 606-12.
- [30] T. Sander, H. Harms, J. Podschus, U. Finckh, B. Nickel, A Rolfs et al, Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium, *Biol Psychiatry*, 41 (1997) 299-304.
- [31] P. Gorwood, F. Limosin, P. Batel, M. Hamon, J. Adès, C. Boni, The A9 allele of the DAT gene is associated with delirium tremens and alcohol-withdrawal seizure, *Biol Psychiatry*, 53 (2003) 85-92.
- [32] L.G. Schmidt, H. Harms, S. Kuhn, H. Rommelspacher, T. Sander, Modification of alcohol withdrawal by the A9 allele of the dopamine transporter gene, *Am J Psychiatry*, 155 (1998) 474-8.
- [33] C. Wernicke, M. Smolka, J. Gallinat, G. Winterer, L.G. Schmidt, H. Rommelspacher, Evidence for the importance of the human dopamine transporter gene for withdrawal symptomatology of alcoholics in a German population, *Neurosci Lett.*, 333 (2002) 45-8.
- [34] F. Limosin, J.Y. Loze, C. Boni, L.P. Fedeli, M. Hamon, F. Rouillon, J. Adès, P. Gorwood, The A9 allele of the dopamine transporter gene increases the risk of visual hallucinations during alcohol withdrawal in alcohol-dependent women, *Neuroscience Letters*, 362 (2004) 91-94.
- [36] J.C. Antony, J.E. Helzer, Epidemiology of drug dependence, in :Textbook of Psychiatric Epidemiology, M.T. Tsuang, M. Tohen., G.E. Zahner (Eds), Wiley-Liss, New York, 1995, pp 361-406.
- [33] J. Volavka, P. Czobor, D.W. Goodwin, W.F. Gabrielli Jr, E.C. Penick and S.A. Mednick et al., The electroencephalogram after alcohol administration in high-risk men and the development of alcohol use disorders 10 years later Preliminary findings, *Arch Gen Psychiatry* 53 (1996) pp. 258–263.

Figure 1: Two types of interaction between a gene (with or without the muted allele) and one environmental factor (with a quantitative variable exposure to an environmental risk factor) in order to explain an increased global risk for a disorder.




Table I: One-year prevalence of DSM-IV abuse and dependence in the USA (NESARC study) [7].

<u>Drug</u>	<u>Abuse</u>		<u>Dependence</u>	
	<u>%</u>	<u>(s.e.)</u>	<u>%</u>	<u>(s.e.)</u>
Tranquilizer	0.08	(0.02)	0.05	(0.01)
Sedative	0.09	(0.02)	0.07	(0.01)
Amphetamine	0.09	(0.02)	0.07	(0.02)
Hallucinogen	0.12	(0.02)	0.02	(0.01)
Cocaine	0.13	(0.02)	0.13	(0.02)
Opioid	0.24	(0.04)	0.11	(0.02)
Cannabis	1.13	(0.06)	0.32	(0.04)

Table II: Demographic characteristics and psychiatric morbidity of subjects with, versus without, DSM-IV drug and/or alcohol use disorder (NESARC study [7]).

Characteristics		Use disorder			
		Alcohol	Drug (any)	Alcohol and drug	None
Gender	Male	69.4 (1.04)	60.1 (2.97)	73.9 (2.64)	45.7 (0.32)
	Female	30.6 (1.04)	39.9 (2.97)	26.1 (2.64)	54.3 (0.32)
Ethnicity	White	75.8 (1.85)	68.5 (2.90)	68.5 (3.06)	70.6 (1.61)
	Black	8.7 (0.67)	15.8 (2.14)	11.5 (1.83)	11.2 (0.65)
	Asian	2.3 (0.48)	3.6 (1.61)	2.6 (0.99)	4.6 (0.56)
	Hispanic	10.8(1.59)	8.9 (1.88)	11.0 (1.82)	11.7 (1.23)
Age	18-29	38.3 (1.18)	47.8 (3.30)	65.0 (3.02)	19.7 (0.37)
	30-44	37.0 (1.09)	33.8 (3.19)	25.9 (2.63)	30.4 (0.33)
	45-64	21.6 (0.98)	15.9 (2.31)	9.1 (1.85)	32.3 (0.32)
	>65	3.2 (0.34)	2.6 (0.78)	0.1 (0.07)	17.6 (0.37)
Marital status	Married	47.7 (1.08)	45.0 (3.14)	20.2 (2.21)	63.4 (0.50)
	Separated	16.7 (0.85)	12.8 (1.96)	16.6 (2.18)	17.6 (0.24)
	Never married	35.6 (1.21)	42.2 (3.04)	63.2 (2.80)	19.0 (0.49)
Education	<high school	12.2 (0.98)	18.3 (2.51)	18.2 (2.67)	15.9 (0.49)
	High school	27.9 (1.09)	38.1 (3.29)	33.3 (2.77)	29.3 (0.56)
	> high school	59.8 (1.32)	43.6 (2.93)	48.4 (3.01)	54.8 (0.63)
Income (US \$)	0-20.000	39.3 (1.22)	66.1 (3.31)	65.4 (2.89)	47.5 (0.59)
	20.000-35.000	25.8 (1.06)	18.7 (2.69)	23.1 (2.45)	22.4 (0.36)
	35.000-70.000	25.5 (1.00)	11.3 (2.13)	9.7 (1.61)	21.9 (0.40)
	>70.000	9.4 (0.71)	4.0 (1.68)	1.8 (0.72)	8.2 (0.38)
Urbanicity	Urban	79.6 (1.83)	84.3 (2.60)	78.4 (3.09)	80.3 (1.62)
	Rural	20.4 (1.83)	15.7 (2.60)	21.6 (3.09)	19.7 (1.62)
Personality	Disorder	25.3 (1.00)	44.0 (3.45)	50.8 (3.05)	13.2 (0.33)
	No disorder	74.7 (1.00)	56.0 (3.45)	49.2 (3.05)	86.8 (0.33)
Past-year independent mood disorder					
	Yes	16.4 (0.81)	27.5 (2.58)	35.3 (3.32)	8.1 (0.21)
	No	83.6 (0.81)	72.5 (2.58)	64.7 (3.32)	91.9 (0.21)
Past-year independent anxiety disorder					
	Yes	15.6 (0.86)	24.0 (2.66)	26.5 (2.82)	10.4 (0.32)
	No	84.4 (0.86)	76.0 (2.66)	73.5 (2.82)	89.6 (0.32)

Table III: Risk increase (adjusted odds ratio with 95% confidence interval) for alcohol abuse or dependence of patients with drug abuse or dependence (controlling the role of sociodemographic factors, personality disorder, 12-month independent mood disorder and independent anxiety disorder).

<u>Drug</u>	<u>Abuse</u>	<u>Dependence</u>
Sedative	5.3 (2.44–11.31)	1.8 (0.65– 4.93)
Tranquilizer	7.1 (2.52–20.17)	4.0 (1.30– 12.16)
Cannabis	6.2 (4.80– 7.90)	7.3 (3.92– 13.72)
Any	5.7 (4.49– 7.30)	9.9 (6.47– 15.01)
Opioid	6.1 (3.76– 9.91)	12.9 (6.18– 26.89)
Amphetamine	5.2 (2.14–12.59)	20.3 (6.18– 66.94)
Cocaine	10.5 (4.85–22.56)	43.0 (17.83–103.49)

Table IV: Assessing GxE interaction on the basis of presence versus absence of each risk factor (genetic and environmental).

<u>Vulnerability gene (G)</u>	<u>Environmental factor (E)</u>	
	<u>Absent</u>	<u>Present</u>
Absent	RR=1	RR[E]
Present	RR[G]	RR[GxE]
